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Abstract
Background/Objectives—A large intake of walnuts may improve lipid profile and endothelial
function. The effect of moderate walnut consumption is not known. We investigated whether a
moderate intake of walnuts would affect lipid profile, arterial stiffness and platelet activation in
healthy volunteers.
Subjects/Methods—Thirty healthy males were recruited into a single-blind randomised
controlled crossover trial of 4 weeks dietary walnut supplementation (15 g/day) and 4 weeks
control (no walnuts). Arterial stiffness was assessed using pulse waveform analysis to determine
the augmentation index and augmented pressure. Platelet activation was determined using flow
cytometry to measure circulating platelet-monocyte aggregates.
Results—There were no differences in lipid profile after 4 weeks of walnut supplementation
compared with control. Dietary intake of alpha-linolenic acid was increased during the walnut diet
(2.1±0.4 g/day versus 0.7±0.4 g/day, P<0.0001). There were no differences in augmentation index
or augmented pressure during walnut supplementation. Walnut supplementation did not affect
platelet-monocyte aggregation .
Conclusions—Dietary intervention with a moderate intake of walnuts does not affect lipid
profile, arterial stiffness or platelet activation in man. Our results suggest that the potentially
beneficial cardiac effects of walnuts may not be apparent at lower and more practical levels of
consumption.
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Introduction
Frequent consumption of nuts may be protective against coronary heart disease (Hu and
Stampfer, 1999). Nuts are rich in unsaturated fatty acids and contain potentially beneficial
compounds including anti-oxidants, L-arginine, fibre, and folic acid (Kris-Etherton et al.,
1999). Walnuts are unique because they also contain high levels of α-linolenic acid, a plant
derived omega-3 fatty acid that may confer additional cardiac protection (de Lorgeril and
Salen, 2004). Dietary intervention studies have demonstrated that a large intake of walnuts
can reduce LDL cholesterol (Banel and Hu, 2009). In addition, walnuts may improve
endothelial function in patients with hyperlipidemia or diabetes (Ma et al., 2010; Ros et al.,
2004). However, the precise mechanisms through which walnuts confer their putative
cardiac benefits remains uncertain.
The endothelium plays a critical role in the regulation of vascular smooth muscle tone,
thrombosis and inflammation. Vascular smooth muscle tone is an important determinant of
central arterial pressure and arterial stiffness. Large artery stiffness, wave reflections and
central pulse pressure are inversely associated with endothelial function and can be
measured non-invasively using pulse waveform analysis (McEniery et al., 2006). The
endothelium also regulates local platelet activation and aggregation through the release of
paracrine factors, such as nitric oxide and prostacyclin. Platelet-leukocyte aggregates are
highly sensitive markers of platelet activation that are closely related to impaired endothelial
vasomotor function (Robinson et al., 2006). They contribute to the development of
atherothrombosis and are elevated in coronary heart disease and acute coronary syndromes
(Sarma et al., 2002).
Marine-derived long chain omega-3 fatty acids reduce arterial compliance and platelet
activation (Din et al., 2004; Din et al., 2008). We therefore hypothesised that dietary
intervention with walnuts, rich in plant-derived omega-3 fatty acids, would reduce arterial
stiffness and platelet activation in humans. Previous intervention studies have asked
participants to consume large amounts of walnuts (30-108 grams or approximately 8-27
whole walnuts daily) providing up to 50% of the total dietary fat intake. This proportion of
fat energy from walnuts may be too high to be considered practical, and no previous trials
have assessed the effect of a more realistic intake of walnuts. In the present study we
examined the effect of a moderate intake of walnuts on lipid profile, arterial stiffness and
platelet activation.
Subjects and Methods
Study participants and design
Thirty healthy male volunteers were enrolled into the study. Exclusion criteria included
those taking regular medication, those with clinical evidence of atherosclerotic vascular
disease, hypertension, diabetes mellitus, hypercholesterolemia, an intercurrent illness likely
to be associated with an acute phase inflammatory response, and renal or hepatic
insufficiency. Ethical approval was obtained from the Lothian Research Ethics Committee
and all subjects provided written informed consent.
Participants were randomised to 4 weeks of walnut supplementation (15 g / day) or 4 weeks
of control (no walnuts) in a single-blind randomised crossover trial. Block randomization
was used and investigators were blinded as to whether participants were in the walnut
intervention or control period. The walnut intake was calculated to provide levels of alpha-
linolenic acid similar to the current American Heart Association recommendations and trials
showing a reduction in cardiac events with diets rich in alpha-linolenic acid (de Lorgeril et
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al., 1994; Kris-Etherton et al., 2002). Lipid profile, platelet-leukocyte aggregation, and
arterial stiffness were assessed at the end of each 4 week period.
Dietary intervention
Participants were provided with walnuts at the beginning of the dietary intervention phase
and asked to consume 15 g of walnuts daily in addition to their habitual diets. No other
specific dietary advice was provided and there were no restrictions on calorie or fat intake.
For the control phase of the study, participants were simply asked to continue with their
usual diets. Similar to previous studies, we did not include a washout period between diets
as diet-induced lipoprotein changes stabilize in less than 4 weeks (Kris-Etherton and
Dietschy, 1997). Participants completed a 3-day weighed food diary to assess intake of
omega-3 fatty acids during each phase of the study. Subsequent dietary analysis was
performed by a qualified dietician using the CompEat Nutritional Analysis Software
program (Nutrition Systems, UK), enabled with McCance and Widdowson's reference food
composition tables
Blood collection protocol
Peripheral venous blood was drawn from a large antecubital vein with a 19 gauge needle and
anticoagulated with the direct thrombin inhibitor D-Phenylalanine-L-prolyl-L-arginine
chloromethyl ketone (75 μmol, Cambridge Biosciences). Whole blood was then
immunolabelled within 5 minutes of phlebotomy for subsequent flow cytometric analysis of
platelet-monocyte aggregates.
Flow cytometry
The following reagents were used: fluorescein isothiocyanate-conjugated CD42a (GRP-P,
IgG1), and isotype control IgG1 were obtained from Serotec Ltd (Oxford, UK),
phycoerythrin-conjugated CD14 (Tuk-4, IgG2a) was obtained from Dako Cytomation
(Buckinghamshire, UK) and FACS-Lyse was obtained from Becton-Dickinson (Cowley,
UK). The methods are as previously described (Harding et al., 2007). Briefly, aliquots of
whole blood were incubated with anti-CD14, anti-CD42a and isotype matched controls.
Thereafter, samples were fixed and the red cells lysed. Samples were analysed using a
Coulter EPICS XL flow cytometer equipped with a 488 nm wavelength laser (Beckman
Coulter, High Wycombe, UK). Samples were initially analysed with the flow cytometer
triggered on forward scatter and then by triggering on FL-2 to identify CD14 positive
monocytes. Platelet-monocyte aggregates were defined as monocytes positive for CD42a.
All results are expressed as percentage of positive cells. Analyses were performed using
EXPO 32 software (Beckman Coulter, High Wycombe, UK). The mean coefficient of
variation for the percentage of platelet-monocyte aggregates is 7.8%.
Pulse waveform analysis
Arterial stiffness was measured non-invasively with the SphygmoCor system (AtCor
Medical). Measurements were taken in a quiet, temperature controlled room after subjects
had been in the recumbent position for a 15 minute rest period. Peripheral pressure
waveforms were obtained using applanation tonometry of the radial artery with a pressure
sensitive micromanometer (Millar Instruments). A generalised transfer function was used to
derive the corresponding aortic pressure waveform. The first systolic peak of this waveform
is a result of left ventricular ejection and the second systolic peak is caused by wave
reflection from the periphery. The augmented pressure was defined as the difference
between the first and second systolic peaks. The augmentation index was the augmented
pressure expressed as a percentage of the pulse pressure. Our reproducibility measures
demonstrate within-observer differences of 0.4 ± 1.5% for the augmentation index and 0.3 ±
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0.6 mm Hg for augmented pressure. Peripheral blood pressure measurements were
performed using an automated upper arm blood pressure monitor (Omron 705IT, Omron
Healthcare).
Statistical methods
Continuous variables are reported as mean ± standard deviation. Statistical analyses were
performed using 2-tailed Student's t-tests. All calculations were performed using GraphPad
Prism (Graph Pad Software). Statistical significance was taken p<0.05.
Results
Baseline characteristics
Baseline characteristics for the study population are given in Table 1. Study participants
were young and had a normal body mass index, blood pressure and lipid profile. Two
subjects were cigarette smokers and the average alcohol intake was within recommended
limits (15±10 units per week). In terms of ethnic origin, 22 participants were North
European Caucasians, 5 were Indian Asians and 3 were of Far East Asian origin.
Effect of walnut supplementation on lipid profile and intake of omega 3 fatty acids
Total and LDL cholesterol were lower than baseline after both the walnut intervention and
control diets (P<0.01), but there were no differences in lipid profile between groups at the
end of each 4 week period (Table 2). Dietary intake of alpha-linolenic acid was markedly
increased during the walnut diet (2.1±0.4 g/day versus 0.7±0.4 g/day; P<0.0001). There
were no changes in consumption of the marine-derived omega-3 fatty acids
eicosapentaenoic acid (0.2±0.2 g/day versus 0.2±0.3 g/day) or docosahexaenoic acid
(0.2±0.3 g/day versus 0.3±0.3 g/day) during walnut supplementation compared with control.
Effect of walnut supplementation on measures of arterial stiffness
Dietary intervention with walnuts did not affect heart rate, peripheral blood pressure, or
central aortic pressures compared with control (Table 3). Measures of arterial stiffness did
not change from baseline after either walnut supplementation or control, and there were no
differences observed in augmentation index (−6.6±6.5 % versus −8.4±6.3 %), or augmented
pressure (−2.2±2.1 mmHg versus −2.7±2.4 mmHg) or at the end of each 4 week period
(Figure 1).
Effect of walnut supplementation on platelet-leukocyte aggregation
Platelet-monocyte aggregates were lower campared with baseline after both the walnut
intervention (18.5±7.2 % versus 22.0±6.8%, P=0.004) and control diets (19.5±7.2 % versus
22.0±6.8%; P=0.048). Platelet-neutrophil aggregates also fell from baseline after the walnut
intervention (5.2±1.8 % versus 7.2±3.0%, P=0.0003) and control diets (5.5±2.2 % versus
7.2±3.0%; P=0.0027). However, there were no differences in platelet-monocyte aggregation
(18.5±7.2 % versus 19.5±7.2 %) or platelet-neutrophil aggregation (5.2±1.8 % versus
5.5±2.2%) between walnut intervention and control diets at the end of each 4 week period
(Figure 2).
Discussion
We have demonstrated that dietary supplementation with a moderate intake of walnuts does
not affect lipid profile, arterial stiffness or platelet activation in healthy subjects. This is in
contrast with previous studies which have shown that heavy consumption of walnuts as part
of a low-fat or “Mediterranean” diet can reduce LDL cholesterol and improve endothelial
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function. The present study is the first dietary intervention trial to assess the efficacy of
moderate rather than large walnut consumption on markers of cardiovascular risk.
Data on the effects of walnut consumption on lipid profile have been inconsistent. Whilst
several randomised trials have found a reduction in total or LDL cholesterol with walnuts
(Iwamoto et al., 2002; Ros et al., 2004; Sabate et al., 1993; Tapsell et al., 2004; Torabian et
al., 2010; Zambon et al., 2000), others have shown no effect (Chisholm et al., 1998; Morgan
et al., 2002; Mukuddem-Petersen et al., 2007; Spaccarotella et al., 2008; Tapsell et al.,
2009). Overall, a meta-analysis of 11 trials found that high-walnut enriched diets reduced
total and LDL cholesterol by 4.9% and 6.7%, respectively (Banel and Hu, 2009).
The most likely explanation for the lack of effect on lipid parameters in our study is the
lower amount of walnuts consumed (15 grams daily) compared to previous trials. Studies
demonstrating reductions (6-16%) in serum LDL cholesterol concentrations with walnuts
have required participants to consume between 40 to 84 grams of walnuts per day (Iwamoto
et al., 2002; Ros et al., 2004; Sabate et al., 1993; Zambon et al., 2000). Furthermore, in these
studies walnuts isocalorically replaced other fat containing foods as part of low fat, low
cholesterol or “Mediterranean” style diets, whilst our study participants were free-living. It
is not possible to know whether the beneficial lipid effects in previous studies were
specifically due to walnut intake or the replacement of other sources of dietary fat.
Most previous trials have investigated patients with hyperlipidaemia, and the relatively low
baseline cholesterol in our study population may have contributed to the neutral lipid results.
A recent trial found that lipid-lowering with walnut supplementation was only evident in
patients with higher cholesterol levels; there was no benefit in those with baseline
cholesterol concentrations <4.94 mmol/l (Torabian et al., 2010). The only two trials in
normolipidaemic patients where walnuts reduced cholesterol levels required a large intake of
>50 grams per day (Iwamoto et al., 2002;Sabate et al., 1993). It is possible that
supplementation with a smaller amount of walnuts is not sufficient to alter lipid parameters
in a young, low-risk, normolipidaemic population.
The present study is the first trial to assess the effect of walnut consumption on arterial
stiffness and platelet activation. We have previously demonstrated that dietary intervention
with fish rich in marine-derived omega 3 fatty acids reduces platelet-monocyte aggregates, a
highly sensitive marker of platelet activation (Din et al., 2008). However, supplementation
with walnuts rich in plant-derived omega 3 fatty acids did not reduce platelet-monocyte
aggregates, and there was also no change in the augmentation index or augmented pressure.
Although we did not study and cannot exclude an effect with heavy walnut intake, our
results indicate that any potential cardiac benefits of moderate walnut consumption are
unlikely to be mediated through effects on platelet activation or arterial stiffness.
The large amount of walnuts consumed in many of the previous dietary intervention trials
provided up to 20% of total energy and 55% of daily total fat intake. There have been
concerns that this proportion of fat energy from walnuts may be too high to be practical or
sustainable in a non-research setting (Banel and Hu, 2009; Feldman, 2002). In 2004, the
Food and Drug Administration issued a qualified health claim for walnuts in response to a
petition from the California Walnut Commission (Food and Drug Administration, Center for
Food Safety and Applied Nutrition, 2004). Their report recognised that the clinical studies
used high daily walnut intakes and that there were no data from which to extrapolate
beneficial effects to lower amounts. The present study provides some data to address these
concerns, and suggests that a smaller and more practical intake of walnuts may not be
sufficient to improve lipid parameters or cardiovascular risk markers.
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Our study has potential limitations which should be recognised. Firstly, the sample size is
relatively small. However, the power of the study is augmented by the cross over design and
was considered sufficient to detect important changes in outcome measures. Previous studies
demonstrating improved lipid parameters and endothelial function with walnuts have had
fewer participants. We therefore believe it is unlikely that our neutral results are due to a
lack of power. Secondly, we cannot fully exclude a lack of adherence to the assigned diet as
a cause of our neutral findings. Although the weighed food diary analysis suggested
complete adherence, this is a self-reported and imperfect measure of compliance.
Finally, we did not include a run-in period prior to randomisation. All eligible subjects were
randomised and an intention-to-treat analysis performed in order to maximise the
applicability and external validity of the study. Whilst there were no differences between the
diets at the end of each 4 week period, both the walnut intervention and control diets
reduced cholesterol concentrations and platelet-leukocyte aggregates compared with
baseline. These changes may reflect a modification in participants' dietary habits after
randomistation, independent of their dietary assignment, and could have reduced our ability
to detect subtle differences between diets.
Conclusions
We have demonstrated that dietary intervention with a moderate intake of walnuts does not
affect lipid profile, arterial stiffness or platelet activation in healthy male volunteers. This is
in contrast to previous studies in which large amounts of walnuts, as part of iso-caloric low
fat diets, were found to reduce serum LDL cholesterol concentrations and improve
endothelial function. Our results suggest that the potentially beneficial effects of walnuts on
lipid parameters and cardiovascular biomarkers may not be apparent at lower and more
practical levels of consumption. However, we cannot exclude the possibilty that the neutral
results are due to either small study size or lack of adherence to the walnut intervention.
Further studies are necessary to determine whether larger amounts of walnuts might affect
arterial stiffness or platelet activation. Longer trials are required to establish if the higher
levels of walnut consumption associated with improved lipid profiles or endothelial function
can be sustained over time and reduce clinical end-points.
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Figure 1.
Effect of dietary intervention with walnuts on augmentation index (A) and augmented
pressure (B). Median (horizontal line), interquartile range (box) and 95% confidence
intervals (bars).
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Figure 2.
Effect of dietary intervention with walnuts on platelet-monocyte and platelet-leukocyte
aggregates. Mean±SD.
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TABLE 1
Baseline characteristics
Age, years 23±3
Body mass index, kg/m2 24.5±2.3
Systolic blood pressure, mm Hg 117±9
Diastolic blood pressure, mm Hg 60±7
Total cholesterol, mmol/l 4.57±1.06
LDL cholesterol, mmol/l 2.70±0.92
HDL cholesterol, mmol/l 1.32±0.24
Triacylglycerol, mmol/l 1.22±0.58
Augmentation index, % −5.3±6.9
Augmented pressure, mm Hg −1.8±2.5
Platelet-monocyte aggregates, % 22.0±6.8
Platelet-neutrophil aggregates, % 7.2±3.0
Mean±SD
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TABLE 2
Effect of walnut supplementation on serum lipid profile
Control Walnuts P value
Total cholesterol, mmol/l
change from baseline, mmol/l
4.37±1.01
−0.33±0.39
4.25±0.99
−0.20±0.37 0.11
LDL cholesterol, mmol/l
change from baseline, mmol/l
2.46±0.85
−0.40±0.47
2.30±0.84
−0.24±0.37 0.10
HDL cholesterol, mmol/l
change from baseline, mmol/l
1.24±0.19
−0.09±0.19
1.24±0.26
−0.08±0.15 0.85
Chol:HDL chol ratio
change from baseline, mmol/l
3.47±0.85
−0.13±0.61
3.39±0.85
−0.05±0.62 0.63
Triacylglycerol, mmol/l
change from baseline, mmol/l
1.45±0.74
0.33±0.86
1.55±0.93
0.23±0.59 0.61
Mean±SD.
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Table 3
Haemodynamic effects of walnut supplementation
Control Walnuts P Value
Heart rate, beats per minute 64±8 68±11 0.08
Peripheral sys tolic blood pressure, mmHg 117±8 120±10 0.07
Peripheral diastolic blood pressure, mmHg 62±5 63±8 0.66
Peripheral pulse pressure, mmHg 54±8 57±9 0.11
Mean arterial pressure, mmHg 77±6 79±8 0.29
Central aortic systolic pressure, mmHg 96±7 98±8 0.09
Central aortic diastolic pressure, mmHg 63±5 64±8 0.54
Mean±SD.
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